Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Contributors to Diagnostic Error or Delay in the Acute Care Setting: A Survey of Clinical Stakeholders
Redmond, Sarah , Barwise, Amelia , Zornes, Sarah, Pinevich, Yuliya , Soleimani, Jalal , Leppin, Aaron L. , Pickering, Brian W. , Minteer, Sarah A. , Herasevich, Svetlana , Leppin, Aaron, Barwise, Amelia K , Dong, Yue , LeMahieu, Allison

Mayo Clinic

Health Services Insights | September 13, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/11786329221123540 | PMID 36119635 Get It

Diagnostic error or delay (DEOD) is common in the acute care setting and results in poor patient outcomes. Many factors contribute to DEOD, but little is known about how contributors may differ across acute care areas and professional roles. As part of a sequential exploratory mixed methods research study, we surveyed acute care clinical stakeholders about the frequency with which different factors contribute to DEOD. Survey respondents could also propose solutions in open text fields. N = 220 clinical stakeholders completed the survey. Care Team Interactions, Systems and Process, Patient, Provider, and Cognitive factors were perceived to contribute to DEOD with similar frequency. Organization and Infrastructure factors were perceived to contribute to DEOD significantly less often. Responses did not vary across acute care setting. Physicians perceived Cognitive factors to contribute to DEOD more frequently compared to those in other roles. Commonly proposed solutions included: technological solutions, organization level fixes, ensuring staff know and are encouraged to work to the full scope of their role, and cultivating a culture of collaboration and respect. Multiple factors contribute to DEOD with similar frequency across acute care areas, suggesting the need for a multi-pronged approach that can be applied across acute care areas.
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ali, Haris , Dunbar, Andrew , Elshoury, Amro, Gundabolu, Krishna , Jain, Tania , Jamieson, Catriona , Kaesberg, Paul, Madanat, Yazan F. , McMahon, Brandon , Nadiminti, Kalyan , Pardanani, Animesh , Rein, Lindsay , Salit, Rachel B. , Stein, Brady L. , Vachhani, Pankit , Wadleigh, Martha , Wall, Sarah , Ward, Dawn C., Bergman, Mary Anne, Hochstetler, Cindy L., Madanat, Yazan , Gerds, Aaron T. , Gotlib, Jason , Bose, Prithviraj , George, Tracy I. , Hexner, Elizabeth O. , Hobbs, Gabriela , Kuykendall, Andrew , Mohan, Sanjay , Oh, Stephen T. , Podoltsev, Nikolai , Talpaz, Moshe

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 1033-1062

10.6004/jnccn.2022.0046 | PMID 36075392 Get It

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
Second and Third Line Treatment Strategies in Multiple Myeloma: a Referral-Center Experience
Goldman‐Mazur, Sarah , Rajkumar, S. Vincent , Kapoor, Prashant , Lacy, Martha Q. , Gertz, Morie A. , Buadi, Francis K. , Hayman, Suzanne R. , Dingli, David , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S Vincent , Gertz, Morie A , Buadi, Francis K , Dingli, David , Visram, Alissa , Dispenzieri, Angela , Gonsalves, Wilson I. , Muchtar, Eli , Leung, Nelson

Mayo Clinic

No container title available | September 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1995380/v1 Get It

Abstract The treatment landscape for relapsed multiple myeloma (MM) has increased. In this study we aimed to characterize 2nd (n = 1439) and 3rd (n = 1104) line regimens and compare the results between subgroups based on the year of treatment initiation (2nd line: 2003–2008, 2009–2015, 2016–2021; 3rd line: 2004–2009, 2010–2015, and 2016–2021). In both 2nd and 3rd line we observed increasing use of novel agents (from 78–95% and from 77–95%, respectively) and triplet regimens (from 15–69% and from 21–71%, respectively). Most frequently used regimens in the last studied periods included lenalidomide-dexamethasone (RD; 14%), carfilzomib-RD (12%) and daratumumab-RD (10%) for 2nd line, and daratumumab-pomalidomide-dexamethasone (11%) and daratumumab-RD (10%) for 3rd line. Median time to next treatment from 2nd line therapy has improved from 10.4 months (95% CI 8.4–12.4) to 16.6 months (95% CI 13.3–20.3; p < 0.001). The median overall survival from 1st relapse increased from 30.9 months (95% CI 26.8–183.0) to 65.8 months (95% CI 50.7–72.8; p < 0.001). Over the last two decades more patients were treated with newer agents and triplets for relapsed MM. The landscape of regimens has become more diverse, and the survival after 1st relapse is continually improving.
THE EFFECT OF GAIT COMPLIANCE ON LOADING IN THE LOWER LIMB
Schmitt, Daniel , Little, Sarah E , Trentadue, Taylor P.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 6, 2022 | Volume: 54 | Issue: 9S | Pages: 285-285

10.1249/01.mss.0000878580.14985.7a Get It

Methodological Quality Of The Work Of Breathing During Exercise: A Systematic Review
Morris, Sarah J. , Erram, Jyotika, Duke, Joseph W. , Hubbard, Colin D., Smith, Joshua R. , Kelley, Eli F. , Cross, Troy J.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 6, 2022 | Volume: 54 | Issue: 9S | Pages: 279-279

10.1249/01.mss.0000878508.61830.21 Get It

Awareness, perceptions, and characteristics of internal medicine residents as role models
Toro-Tobón, David , Thornton, Sarah , Toro-Tobon, David

Mayo Clinic

The Clinical Teacher | September 6, 2022 | Volume: 19 | Issue: 6 | Pages: No page available

10.1111/tct.13526 | PMID 36065504 Get It

Abstract Background Role modelling is an essential component of medical education in which trainees incorporate observed characteristics into their personal behaviour and practice style. Data on residents as role models is limited. There are no previous quantitative studies addressing residents as role models from the resident's perspective. Objective This study aimed to dissect the awareness, perception, and positive characteristics of internal medicine (IM) residents as role models. Methods This was a cross sectional study, in which 59 medical students (MS) and 64 IM residents from Medstar Georgetown University Hospital completed a questionnaire on role modelling. Descriptive and comparative analyses between both groups were conducted. Findings Most participants perceived IM residents as role models, but MS were more likely to report that IM residents lack awareness of their role model status. While MS perceived spending more hours with residents, the residents perceived dedicating more of the time spent together to teaching. Most participants denied previous training in role modelling but expressed interest in receiving formal role modelling training. Most participants reported MS behaviours were modified based on their observations of IM residents; however, while most of these behaviours were positive, there were also negative behaviours reported. Conclusion There was a discrepancy between perception and awareness of residents as role models. This characterisation of IM residents as role models sets the ground for the design of interventions to increase awareness and create educational interventions aimed to support residents in their teaching role.
Anticoagulation Prescribing Patterns in Intensive Care Unit Patients Admitted with Prehospital Direct Oral Anticoagulant Therapy: A Single Academic Center Experience
Lal, Amos , Chalmers, Sarah , Wieruszewski, Patrick M. , Park, John G. , MUKHTAR, Osama, Chalmers, Sarah J, Wieruszewski, Patrick M , Lal, Amos , Mukhtar, Osama , Karp, John

Mayo Clinic

Hospital Pharmacy | September 5, 2022 | Volume: 58 | Issue: 1 | Pages: 84-91

10.1177/00185787221122656 | PMID 36644754 Get It

Objective:To describe the current prescribing practices of direct oral anticoagulants (DOACs) in intensive care unit (ICU) patients and the associated clinical outcomes, including the incidence of major bleeding episodes and the need for intervention (endoscopic, surgical, or interventional radiology guided). Design:Observational, retrospective chart review. Setting and Participants:Single large academic center study. Participants included patients with critical illness who were admitted to the intensive care units (ICU) at Mayo Clinic from January 1st, 2012, until May 4th, 2018. Adult ICU patients with a DOAC (apixaban, rivaroxaban, dabigatran, or edoxaban) listed as one of the active medications at the time of hospital admission were included. Results:37 249 patients in medical and surgical intensive care units were screened for the study period. After excluding patients who did not qualify, 558 unique encounters were included. The median age was 69 (IQR 59-78) years; most patients were male, white Caucasians, and had a median SOFA score of 4. After excluding the patients who had major bleeding episodes in the first 24 hours, 188 (39%) were continued on the same DOAC therapy, 204 (42%) were discontinued without transitioning to another agent, and 95 (20%) were transitioned to another agent. Finally, 410 (84%) were dismissed on DOAC therapy at the end of hospitalization. The difference in the continuation rate of the same DOAC agent beyond 24 hours, discontinuation without transition to an alternate agent, or discontinuation of DOAC with a transition to an alternate anticoagulation agent was not statistically significant ( P = .60). A total of 52 major bleeding events were identified. Gastrointestinal bleeding was the most common bleeding complication [n (%): 34 (65)], followed by intra-abdominal and peri-procedural bleeding [7 (13.5) and 7 (13.5)]. Thirty-three (65%) patients had a major bleeding complication requiring intervention. Conclusions:Our single-center retrospective study describes the current prescribing practices and preliminary outcomes in ICU patients with prehospital use of DOACs. Up to 20% of the patients were transitioned to a different agent within 24 hours of ICU admission, whereas a significant proportion of patients (42%) had anticoagulation discontinued altogether. Most patients who suffered a major bleeding episode required either endoscopic or surgical intervention to control bleeding.
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Roth, Michael , Parsons, Susan K. , Ganz, Patricia A. , Wagner, Lynne I. , Alexander, Sarah , Bingen, Kristin , Cella, David , Henry, N. Lynn , Indelicato, Daniel J. , Johnson, Rebecca H. , Miller, Tamara P. , Rosenberg, Shoshana M. , Thanarajasingam, Gita , Roth, Michael E , Thanarajasingam, Gita , Reeve, Bryce B. , Salsman, John M , Wagner, Lynne , Henry, N Lynn , K Parsons, Susan , Indelicato, Daniel J , Hinds, Pamela S. , Bober, Sharon L. , Brackett, Julienne , Schmitz, Kathryn H.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 2, 2022 | Volume: 115 | Issue: 1 | Pages: 21-28

10.1093/jnci/djac166 | PMID 36266760 Get It

Abstract Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes. The National Cancer Institute’s Clinical Trials Network AYA PRO Task Force was assembled to reach consensus on a core set of PROs and foster its integration into AYA CCTs. Eight key considerations for selecting the core PRO AYA battery components were identified: relevance to AYAs; importance of constructs across the age continuum; prioritization of validated measures; availability of measures without licensing fees; availability in multiple languages; applicability to different cancer types and treatments; ability to measure different HRQoL domains and toxicities; and minimized burden on patients and sites. The Task Force used a modified Delphi approach to identify key components of the PRO battery. The Patient-Reported Outcomes Measurement Information System (PROMIS) and the PRO Common Terminology Criteria for Adverse Events Measurement System met all criteria and were selected to assess HRQoL and treatment toxicity, respectively. Investigators are rapidly incorporating the recommendations of the Task Force into AYA trials. Inclusion of a standardized assessment of HRQoL and treatment toxicities in AYA CCTs is a vital first step to develop interventions to improve health outcomes for AYAs diagnosed with cancer.
Sequenced treatment after regorafenib and survival in metastatic colorectal cancer: a qualitative clinical review
Babajanyan, Svetlana , Pollack, Megan , Castelo, Sarah, Kavati, Abhishek , Bekaii‐Saab, Tanios

Mayo Clinic

Colorectal Cancer | August 30, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.2217/crc-2022-0006 Get It